• Karina Karina, Louis Martin Christoffel, Rita Novariani, Imam Rosadi, Siti Rosidah, Grady Krisandi, Novy Fatkhurohman, Nurlaela Puspitaningrum, Yuli Hertati, Irsyah Afini, Difky Ernanda, Tias Widyastuti, Alfida Zakiyah, Noor Aini
  • Faculty of Medicine, Universitas Pembangunan Nasional Veteran Jakarta, Jakarta, Indonesia.
  • Email: karina@hayandra.com.
  • Koja Regional Public Hospital, Jakarta, Indonesia.
  • Email: louischristoffel200@gmail.com.
  • Koja Regional Public Hospital, Jakarta, Indonesia.
  • Email: kawungsolo27@gmail.com.
  • Department of Biology, Faculty of Mathematics and Natural Sciences, Mulawarman University, Samarinda, Indonesia.
  • Email: imam.rosadi@hayandra.com.
  • Koja Regional Public Hospital, Jakarta, Indonesia.
  • Email: ochiesan1986@gmail.com.
  • Faculty of Medicine, University of Indonesia, Jakarta, Indonesia.
  • Email: gradykrisandi8@gmail.com.
  • Koja Regional Public Hospital, Jakarta, Indonesia.
  • Email: novyfatkhurohman04@gmail.com.
  • Koja Regional Public Hospital, Jakarta, Indonesia.
  • Email: nurlaelaningrum33@gmail.com.
  • Koja Regional Public Hospital, Jakarta, Indonesia.
  • Email: yulihertati21@gmail.com.
  • HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia.
  • Email: irsyah.afini@hayandra.com.
  • HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia.
  • Email: difky@hayandra.com.
  • HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia.
  • Email: tias.widyastuti@hayandra.com.
  • HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia.
  • Email: alfidazakiyah@hayandra.com.
  • HayandraLab, Hayandra Peduli Foundation, Jakarta, Indonesia.
  • Email: noor@hayandra.com.

ABSTRACT

As pregnant women with COVID-19 have higher mortality rates and as more of them are getting infected, it is crucial to find a more efficacious and safer therapy. Among the various therapies available, intravenous autologous activated platelet-rich plasma (aaPRP) is a potential candidate due to its well-known anti-inflammatory effect and autologous property. To our knowledge as of the writing of this manuscript, this is the first report of intravenous autologous activated platelet-rich plasma therapy in pregnant COVID-19 patients. We reported a case series of pregnant COVID-19 patients, in which two had severe to critical symptoms (age 34 and 26) and two had mild to moderate symptoms (age 41 and 25). The use of intravenous autologous activated platelet-rich plasma was able to ameliorate the hyperinflammatory and hypercoagulability state the patients were in, without any adverse events observed.

News Reporter